Dian Diagnostics Group Co.,Ltd. (SHE:300244)
18.96
+0.01 (0.05%)
Apr 28, 2026, 3:13 PM CST
Dian Diagnostics Group Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 2,108 | 1,830 | 2,973 | 4,200 | 2,189 |
Trading Asset Securities | 444.45 | 384.59 | 418.3 | 450.09 | 427.22 |
Cash & Short-Term Investments | 2,552 | 2,215 | 3,392 | 4,650 | 2,616 |
Cash Growth | 15.24% | -34.70% | -27.06% | 77.76% | 27.40% |
Accounts Receivable | 6,244 | 7,447 | 8,257 | 10,143 | 6,411 |
Other Receivables | 72.89 | 74.52 | 155.62 | 118.75 | 106.73 |
Receivables | 6,317 | 7,522 | 8,413 | 10,262 | 6,518 |
Inventory | 1,548 | 1,635 | 1,509 | 1,434 | 1,332 |
Prepaid Expenses | - | - | - | 0.01 | - |
Other Current Assets | 446.32 | 530.78 | 502.69 | 442.29 | 386.72 |
Total Current Assets | 10,864 | 11,903 | 13,816 | 16,789 | 10,852 |
Property, Plant & Equipment | 1,446 | 1,699 | 1,941 | 1,853 | 1,831 |
Long-Term Investments | 982.18 | 959.9 | 670.41 | 1,084 | 1,011 |
Goodwill | 386.02 | 469.97 | 859.39 | 820.06 | 1,279 |
Other Intangible Assets | 56.31 | 58.42 | 58.99 | 56.64 | 48.6 |
Long-Term Accounts Receivable | - | 7.09 | 25.64 | 37.02 | 55.24 |
Long-Term Deferred Tax Assets | 543.49 | 456.47 | 329.89 | 193.69 | 325.9 |
Long-Term Deferred Charges | 111.73 | 185 | 237.65 | 223.1 | 156.52 |
Other Long-Term Assets | 32.88 | 47.25 | 0.24 | 0.15 | 36.02 |
Total Assets | 14,422 | 15,786 | 17,939 | 21,056 | 15,594 |
Accounts Payable | 1,655 | 1,764 | 1,939 | 3,126 | 2,173 |
Accrued Expenses | 438.41 | 606.44 | 729.11 | 1,151 | 666.24 |
Short-Term Debt | 574.08 | 616.22 | 930.56 | 1,941 | 2,510 |
Current Portion of Long-Term Debt | 933.8 | 1,028 | 470.33 | 593.51 | 474.6 |
Current Portion of Leases | - | 141.57 | 171.44 | 173.71 | 156.38 |
Current Income Taxes Payable | 158.03 | 135.2 | 150.18 | 294.79 | 214.03 |
Current Unearned Revenue | 138.38 | 149.95 | 154.04 | 170.05 | 205.38 |
Other Current Liabilities | 191.45 | 240.41 | 360.21 | 297.21 | 239.58 |
Total Current Liabilities | 4,089 | 4,682 | 4,905 | 7,748 | 6,639 |
Long-Term Debt | 1,007 | 1,594 | 2,330 | 2,968 | 887.5 |
Long-Term Leases | 139.99 | 191.84 | 289.44 | 316.64 | 333.41 |
Long-Term Unearned Revenue | 7.7 | 6.24 | 10.33 | 25.29 | 36.3 |
Long-Term Deferred Tax Liabilities | - | 0.77 | 1.28 | 5.66 | 51.69 |
Other Long-Term Liabilities | 574.13 | 544.21 | 498.53 | 490.13 | 169.96 |
Total Liabilities | 5,818 | 7,019 | 8,035 | 11,554 | 8,118 |
Common Stock | 624.98 | 624.98 | 626.9 | 626.9 | 620.46 |
Additional Paid-In Capital | 1,818 | 1,831 | 1,890 | 1,913 | 1,655 |
Retained Earnings | 4,199 | 4,308 | 5,100 | 4,917 | 3,567 |
Treasury Stock | -199.57 | -199.57 | -49.99 | -9.03 | - |
Comprehensive Income & Other | - | - | -0.02 | - | - |
Total Common Equity | 6,442 | 6,564 | 7,566 | 7,448 | 5,842 |
Minority Interest | 2,162 | 2,203 | 2,339 | 2,054 | 1,634 |
Shareholders' Equity | 8,604 | 8,767 | 9,905 | 9,502 | 7,476 |
Total Liabilities & Equity | 14,422 | 15,786 | 17,939 | 21,056 | 15,594 |
Total Debt | 2,655 | 3,572 | 4,192 | 5,993 | 4,361 |
Net Cash (Debt) | -102.9 | -1,357 | -800.32 | -1,343 | -1,746 |
Net Cash Per Share | -0.17 | -2.20 | -1.28 | -2.15 | -2.80 |
Filing Date Shares Outstanding | 610.85 | 611.1 | 619.45 | 624.98 | 620.46 |
Total Common Shares Outstanding | 610.85 | 611.1 | 624.98 | 626.53 | 620.46 |
Working Capital | 6,775 | 7,221 | 8,911 | 9,041 | 4,212 |
Book Value Per Share | 10.55 | 10.74 | 12.11 | 11.89 | 9.42 |
Tangible Book Value | 6,000 | 6,036 | 6,648 | 6,571 | 4,515 |
Tangible Book Value Per Share | 9.82 | 9.88 | 10.64 | 10.49 | 7.28 |
Buildings | - | 306.51 | 306.51 | 244.53 | 171.42 |
Machinery | - | 2,787 | 2,720 | 2,315 | 2,172 |
Construction In Progress | - | 9.97 | 7.86 | 89.38 | 12.92 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.